ondasdechoque.org
PT-BR

Tendon mechanisms and translational research · Review · 2013

Does shockwave help jumper's knee (kneecap tendon pain)?

This review looked at four small trials of focused shockwave for jumper's knee. Three reported bigger gains in knee scores with shockwave. In the largest trial, which used a placebo comparison, gains were about the same in both groups.

trials, with 171 people
4
sessions, depending on the trial
1–5
weeks of follow-up in the three placebo-controlled trials
12–22

Good to know: Four trials with 171 people. The biggest gain came from the one trial without a placebo group.

van der Worp H, van den Akker-Scheek I, van Schie H, et al. Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA, 2013 · Read the paper ↗

How this study worked

One answer
A review gathers earlier studies to answer one question. Illustration, not to scale.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

What the trials used

Device modality
All four trials used focused ESWT: electromagnetic (two), electrohydraulic (one) or piezoelectric (one).
Session and pulse parameters
Protocols ranged from one to five sessions and 1,000–2,000 impulses; energy flux densities ranged from 0.17–0.25 mJ/mm² where reported.
Co-intervention and comparator
Three trials used placebo ESWT; one used conservative care. Decline-squat training was included with both arms in Peers et al.; Wang et al. control included NSAIDs, physiotherapy, exercise, knee strap and activity modification.

Who took part

171 people with jumper's knee (patellar tendinopathy) in four trials; 89 had shockwave.

Side effects

The review did not report side effects for these four trials.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

Patients with patellar tendinopathy in four RCTs; the review table reports study totals of 40, 19, 50 (with paired tendon count also given) and 62 participants, alongside ESWT group counts. The rest of the review includes mechanistic literature.

Peers — focused ESWT21analyzed

Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.

Peers — placebo ESWT19analyzed

Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.

Taunton et al. — focused ESWT10analyzed

Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.

Taunton et al. — placebo ESWT9analyzed

Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.

Wang et al. — focused ESWT27analyzed

Table reports 27 patients and 30 treated tendons; counts are participants.

Wang et al. — conservative care23analyzed

Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.

Zwerver et al. — focused ESWT31analyzed

Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.

Zwerver et al. — placebo ESWT31analyzed

Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.

VISA-P improvement, Peers trial4 reported outcomes
01
12 weeks

VISA-P improvement, Peers trial

Victorian Institute of Sport Assessment–Patella (VISA-P) Points difference versus control

MD17.4Uncertainty interval unavailable

ESWT versus trial control; source table labels this as improvement compared with control

1 study · 40 participants in this estimate

The review table marks a significant difference; it does not report its p value or CI.

Analysis details and source

Table 1 gives this VISA-P value as improvement compared with control; it does not state the estimate type or uncertainty.

02
12 weeks

VISA-P improvement, Taunton et al. trial

Victorian Institute of Sport Assessment–Patella (VISA-P) Points difference versus control

MD3.7Uncertainty interval unavailable

ESWT versus trial control; source table labels this as improvement compared with control

1 study · 19 participants in this estimate

The review table marks a significant difference; it does not report its p value or CI.

Analysis details and source

Table 1 gives this VISA-P value as improvement compared with control; it does not state the estimate type or uncertainty.

03
10–53 months

VISA-P improvement, Wang et al. trial

Victorian Institute of Sport Assessment–Patella (VISA-P) Points difference versus control

MD47.6Uncertainty interval unavailable

ESWT versus trial control; source table labels this as improvement compared with control

1 study

The review table marks a significant difference; it does not report its p value or CI.

Analysis details and source

Table 1 reports total n=50 / ESWT n=27 and separately total 54 tendons / ESWT 30 tendons; control-arm denominator and uncertainty are not reported in that row.

04
22 weeks

VISA-P improvement, Zwerver et al. trial

Victorian Institute of Sport Assessment–Patella (VISA-P) Points difference versus control

MD0.7Uncertainty interval unavailable

ESWT versus trial control; source table labels this as improvement compared with control

1 study · 62 participants in this estimate

The review table marks no significant difference; this does not establish equivalence.

Analysis details and source

Table 1 gives this VISA-P value as improvement compared with control; it does not state the estimate type or uncertainty.

How treatment was delivered
Device modality

All four trials used focused ESWT: electromagnetic (two), electrohydraulic (one) or piezoelectric (one).

Session and pulse parameters

Protocols ranged from one to five sessions and 1,000–2,000 impulses; energy flux densities ranged from 0.17–0.25 mJ/mm² where reported.

Co-intervention and comparator

Three trials used placebo ESWT; one used conservative care. Decline-squat training was included with both arms in Peers et al.; Wang et al. control included NSAIDs, physiotherapy, exercise, knee strap and activity modification.

HARMS & TOLERABILITY

The review table and narrative do not provide adverse-event results for these four RCTs.

LIMITS OF THE ANALYSIS

Four RCTs differed in protocols, controls and follow-up. PEDro scores were 8, 4, 5 and 9; the largest apparent effect was in the only study without placebo.

Table 1 gives VISA-P improvement differences and a yes/no significance label but omits p values and confidence intervals. Wang et al. reports paired participant/tendon counts; unit handling is unclear in the summary table.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Four RCTs differed in protocols, controls and follow-up. PEDro scores were 8, 4, 5 and 9; the largest apparent effect was in the only study without placebo.
  • Table 1 gives VISA-P improvement differences and a yes/no significance label but omits p values and confidence intervals. Wang et al. reports paired participant/tendon counts; unit handling is unclear in the summary table.
Research review

Source-linked critical reading

Narrative technology review with a systematic clinical component

Reading depthMaterial consulted
Technical source record

Full-text XML read: article body, Table 1 (four RCTs), Table 2, Figures 1–3 captions, discussion and end-matter.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and evidence base

Narrative technology and mechanism review with a focused systematic search and quality appraisal of four RCTs in patellar tendinopathy.

Participants

Four trials enrolled patients with patellar tendinopathy; the review table reports 171 patients in the analyses, 89 of them in ESWT groups (one trial counts 50 patients, 27 with ESWT, and 54 tendons, 30 treated with ESWT).

Intervention modalities

The four trials used focused ESWT generated by electromagnetic, electrohydraulic or piezoelectric devices; impulse counts, energy-flux density, number of sessions and co-interventions varied.

Comparators

Three trials used placebo ESWT; one compared treatment with conservative care. Decline-squat training accompanied both active and placebo arms in one study.

Outcomes

The review table reports between-group VISA-P improvement differences of 17.4, 3.7, 47.6 and 0.7 points; three were labelled statistically significant and one was not. The review does not provide uncertainty intervals or p values for these table entries.

Clinical findings

Evidence was conflicting. The largest improvement came from the only study without a placebo intervention; the higher-quality placebo-controlled study reported no significant difference.

Harms

The review does not synthesize adverse events for the four trials in its table.

Limitations

Only four RCTs were found; diagnostic criteria, disease stage, generators, dose settings and follow-up varied. PEDro scores ranged from 4 to 9. Table-reported VISA-P differences lack CIs and p values, limiting assessment of precision.

Applicability

The article is a dated 2012 review and does not establish current comparative effectiveness. Findings for patellar tendinopathy cannot automatically be generalized to other tendons or to a specific contemporary device.

Research needs

Trials should use consistent diagnosis and tendinopathy-stage criteria, prespecify device and dose parameters, include credible sham controls, and report complete between-group estimates with uncertainty and harms.

THE ORIGINAL SOURCE

Read the original article.

ESWT for tendinopathy: technology and clinical implications.

van der Worp H, van den Akker-Scheek I, van Schie H, Zwerver J. · Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2013

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →